What to watch with FT4 and menopause?

Monitoring FT4 (free thyroxine) during menopause is clinically important, but the provided context lacks specific data on thyroid markers or menopause. Generally, menopause involves a decline in estrogen, which affects thyroid-binding globulin (TBG) and can alter thyroid hormone levels. A normal FT4 does not rule out hypothyroidism, especially if TSH is elevated. Women in perimenopause or menopause have a higher risk of subclinical hypothyroidism, which can worsen symptoms like fatigue, weight gain, and mood swings. FT4 alone is insufficient; a full thyroid panel (TSH, fT3, TPO antibodies) is recommended. Caution: thyroid medication (e.g., levothyroxine) may require dose adjustments due to changing estrogen levels (including from HRT). Iodine and selenium status also matter. Evidence for direct FT4-menopause interactions is moderate (clinical practice), but not supported by the given context. Always consult a doctor before starting supplements or hormone therapy.